← Back to guidelines
Cardiology4 papers

Congenital deficiency of intrinsic factor

Last edited: 4/22/2026

Overview

Congenital deficiency of intrinsic factor typically leads to deficiencies in vitamin B12 absorption, often manifesting as megaloblastic anemia and neurological complications due to impaired DNA synthesis and myelination. This condition is distinct from specific coagulation factor deficiencies like Factor VII deficiency discussed in related abstracts 12.

Diagnosis

  • Clinical Presentation: Megaloblastic anemia, neurological symptoms (e.g., developmental delay, irritability).
  • Laboratory Tests: Low serum vitamin B12 levels, elevated methylmalonic acid and homocysteine levels.
  • Specific Factor Assays: For related coagulation deficiencies, ELISA for Factor VII antigen (F VII Ag) can quantify deficiency; undetectable or markedly reduced levels indicate severe deficiency 2.
  • Management

  • Vitamin B12 Supplementation: Intramuscular vitamin B12 injections are first-line treatment [Expert opinion, inferred].
  • Coagulation Factor Replacement: For severe Factor VII deficiency, fresh frozen plasma (FFP) transfusion is used for acute bleeding episodes and prophylaxis 1.
  • - Prophylactic Regimen: FFP 10 ml/kg administered twice weekly can prevent recurrent intracranial hemorrhages 1.

    Special Populations

  • Pediatrics: Prophylactic FFP therapy effectively prevents recurrent intracranial hemorrhages in infants with severe congenital Factor VII deficiency 1.
  • Comorbidities: Management in patients requiring major surgery (e.g., open-heart surgery) may involve sustained plasma infusion to maintain coagulation factor levels 3.
  • Key Recommendations

  • Initiate Intramuscular Vitamin B12 Therapy for confirmed deficiency to address megaloblastic anemia and prevent neurological damage (Evidence: Expert opinion).
  • Use Fresh Frozen Plasma (FFP) for Severe Factor VII Deficiency: Administer FFP 10 ml/kg twice weekly to prevent recurrent intracranial hemorrhages in pediatric patients 1 (Evidence: Weak).
  • Maintain Coagulation Factor Levels During Surgery: For patients with coagulation deficiencies undergoing major surgery, use plasma infusions to sustain factor levels (Evidence: Weak).
  • References

    1 Kankirawatana S, Mahasandana C, Veerakul G, Seeloem J, Suwantol L, Tanphaichitr V et al.. Successful prophylaxis of intracranial hemorrhage in infants with severe congenital factor VII deficiency. The Southeast Asian journal of tropical medicine and public health 2000. link 2 Boyer C, Wolf M, Rothschild C, Migaud M, Amiral J, Mannucci PM et al.. An enzyme immunoassay (ELISA) for the quantitation of human factor VII. Thrombosis and haemostasis 1986. link 3 Williams TE, Teske D, Craenen J, Miser A, Miser J, Saito H et al.. Pulmonary valvulotomy in Factor XI deficiency. The Thoracic and cardiovascular surgeon 1983. link

    Original source

    1. [1]
      Successful prophylaxis of intracranial hemorrhage in infants with severe congenital factor VII deficiency.Kankirawatana S, Mahasandana C, Veerakul G, Seeloem J, Suwantol L, Tanphaichitr V et al. The Southeast Asian journal of tropical medicine and public health (2000)
    2. [2]
      An enzyme immunoassay (ELISA) for the quantitation of human factor VII.Boyer C, Wolf M, Rothschild C, Migaud M, Amiral J, Mannucci PM et al. Thrombosis and haemostasis (1986)
    3. [3]
      Pulmonary valvulotomy in Factor XI deficiency.Williams TE, Teske D, Craenen J, Miser A, Miser J, Saito H et al. The Thoracic and cardiovascular surgeon (1983)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG